All In Biotech

Drug Trial Radar · NCT04830215

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

A Phase 4, Multicenter, Open-label, Interventional Trial to Assess the Effects on Engagement of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy for the Treatment of Adults With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

122

Actual

Start

Apr 1, 2021

Primary completion

May 27, 2022

Study completion May 27, 2022

Sponsor

Sponsor type
Industry
Collaborators
Lundbeck Canada Inc.; Otsuka Canada Pharmaceutical Inc.
First posted
Apr 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.

Conditions

  • Major Depressive Disorder

Interventions

  • BrexpiprazoleDrug

    Oral brexpiprazole tablets as adjunctive therapy to ADT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in IDS-SR-10 EngagementTime frame: Baseline to Week 8
  2. Change From Baseline in IDS-SR Total ScoreTime frame: Baseline to Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chatham-Kent Clinical Trials Research Centre

    Chatham, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.